Literature DB >> 7441019

Synergistic interaction in vitro with use of three antibiotics simultaneously against Pseudomonas maltophilia.

V L Yu, T P Felegie, R B Yee, A W Pasculle, F H Taylor.   

Abstract

An abbreviated three-dimensional checkerboard titration method was devised to determine whether synergistic interaction of three antimicrobial agents could be found against multidrug-resistant bacteria. Pseudomonas maltophilia was used as the test organism because of its resistance to most commercially available antimicrobial agents, including those active against Pseudomonas aeruginosa. Three-dimensional isobolograms with concave surfaces were formed when synergy occurred. Triple combinations of gentamicin-carbenicillin-rifampin (mean fractional inhibitory concentration index, 0.32) and trimethoprim/sulfamethoxazole-carbenicillin-rifampin (mean fractional inhibitory concentration index, 0.18) were consistently synergistic against 14 clinical isolates of P. maltophilia.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7441019     DOI: 10.1093/infdis/142.4.602

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii.

Authors:  Jimmy Yoon; Carl Urban; Christian Terzian; Noriel Mariano; James J Rahal
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

2.  Prevalence of serotypes of Xanthomonas maltophilia from world-wide sources.

Authors:  B Schable; D L Rhoden; W R Jarvis; J M Miller
Journal:  Epidemiol Infect       Date:  1992-04       Impact factor: 2.451

3.  Characterization of the chromosomal aac(6')-Iz gene of Stenotrophomonas maltophilia.

Authors:  T Lambert; M C Ploy; F Denis; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

4.  Synergistic interactions of ciprofloxacin and extended-spectrum beta-lactams or aminoglycosides against multiply drug-resistant Pseudomonas maltophilia.

Authors:  A W Chow; J Wong; K H Bartlett
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

5.  Serological classification of Xanthomonas maltophilia (Pseudomonas maltophilia) based on heat-stable O antigens.

Authors:  B Schable; D L Rhoden; R Hugh; R E Weaver; N Khardori; P B Smith; G P Bodey; R L Anderson
Journal:  J Clin Microbiol       Date:  1989-05       Impact factor: 5.948

Review 6.  Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia.

Authors:  M Denton; K G Kerr
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

Review 7.  Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

8.  Activity of trimethoprim/sulfamethoxazole plus polymyxin B against multiresistant Stenotrophomonas maltophilia.

Authors:  J L Muñoz; M I García; S Muñoz; S Leal; M Fajardo; J A Garćia-Rodríguez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-11       Impact factor: 3.267

9.  Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital.

Authors:  A J Morrison; K K Hoffmann; R P Wenzel
Journal:  J Clin Microbiol       Date:  1986-07       Impact factor: 5.948

10.  In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia.

Authors:  C D Poulos; S O Matsumura; B M Willey; D E Low; A McGeer
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.